A Comprehensive Review on Omeprazole: Pharmacological Effects and Its Adverse Effects

Amit Kumar; Vandana Sahani; Shivanand Patil

doi:10.55544/jrasb.4.1.4

Authors

Amit Kumar Research Scholar, Department of Pharmacy, Shree Dev Bhoomi Institute of Education Science and Technology (SDBIT), Dehradun, INDIA.
Vandana Sahani Associate Professor, Department of Pharmacy, Shree Dev Bhoomi Institute of Education Science and Technology (SDBIT), Dehradun, INDIA.
Shivanand Patil Professor, Department of Pharmacy, Shree Dev Bhoomi Institute of Education Science and Technology (SDBIT), Dehradun, INDIA.

DOI:

https://doi.org/10.55544/jrasb.4.1.4

Keywords:

Proton Pump inhibitors, Git, pH, Clinical

Abstract

Omeprazole, a widely used proton pump inhibitor (PPI), has become a cornerstone in the treatment of various acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. By inhibiting the proton pump in parietal cells, omeprazole effectively reduces gastric acid secretion, thereby promoting healing and alleviating symptoms associated with hyperacidity. This review aims to provide a comprehensive overview of the pharmacological actions, therapeutic uses, and potential adverse effects of omeprazole. The drug’s mechanism of action, pharmacokinetics, and clinical applications in both acute and chronic conditions are discussed in detail. Additionally, attention is given to the adverse effects associated with its prolonged use, including but not limited to gastrointestinal disturbances, nutrient deficiencies, renal complications, and an increased risk of infections. The balance between its therapeutic benefits and associated risks is explored, with a focus on the clinical decision-making process in prescribing omeprazole. The review also highlights the potential for drug interactions, particularly with medications that alter gastric pH or are metabolized via the cytochrome P450 enzyme system. Overall, while omeprazole remains a highly effective therapeutic agent, its adverse effects necessitate careful consideration, particularly in long-term use or in vulnerable patient populations.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Bium AL. Omeprazole: implications for therapy of peptic ulcer and reflux oesophagitis. Digestion. 1989;44 Suppl 1:87-91.

Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. Am J Gastroenterol. 1998 Nov;93(11):2106-12.

Prasertpetmanee S, Mahachai V, Vilaichone RK. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter. 2013 Aug;18(4):270-3.

Bianchi Porro G, Pace F, Peracchia A, Bonavina L, Vigneri S, Scialabba A, Franceschi M. Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. J Clin Gastroenterol. 1992 Oct;15(3):192-8.

Sontag SJ, Hirschowitz BI, Holt S, Robinson MG, Behar J, Berenson MM, McCullough A, Ippoliti AF, Richter JE, Ahtaridis G. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology. 1992 Jan;102(1):109-18.

Meijer JL, Jansen JB, Lamers CB. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers. Digestion. 1989;44 Suppl 1:31-9.

Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther. 1998 Sep;12(9):893-7.

Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci. 1997 Jun;42(6):1255-9.

9.Sachs G, Wallmark B. The gastric H+,K+-ATPase: the site of action of omeprazole. Scand J Gastroenterol Suppl. 1989;166:3-11.

Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet. 1991 Jan;20(1):38-49.

11.Oosterhuis B, Jonkman JH. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion. 1989;44 Suppl 1:9-17.

Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernandez C, Walsh K, Welch V, Moayyedi P. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017 May;63(5):354-364.

Kahrilas PJ, Shaheen NJ, Vaezi MF., American Gastroenterological Association Institute. Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.e1-5.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): May 15, 2022. Omeprazole.

Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, Chiriac SA, Ciobica A, Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol. 2017 Sep 21;23(35):6500-6515.

Toh JW, Ong E, Wilson R. Hypomagnesaemia associated with long-term use of proton pump inhibitors. Gastroenterol Rep (Oxf). 2015 Aug;3(3):243-53.

Park GJ, Bae SH, Park WS, Han S, Park MH, Shin SH, Shin YG, Yim DS. Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. Drug Des Devel Ther. 2017;11:1043-1053.

Kenngott S, Olze R, Kollmer M, Bottheim H, Laner A, Holinski-Feder E, Gross M. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? Eur J Med Res. 2010 May 18;15(5):220-4.

Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008 Aug 12;179(4):319-26.

Yanagihara GR, de Paiva AG, Neto MP, Torres LH, Shimano AC, Louzada MJ, Annoni R, de Oliveira Penoni ÁC. Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone. Rev Bras Ortop. 2015 Mar-Apr;50(2):232-8.

Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 Apr;37(4):201-11.

Williams S, Miller G, Khoury R, Grossberg GT. Rational deprescribing in the elderly. Ann Clin Psychiatry. 2019 May;31(2):144-152.

Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.

Ferner RE, Allison TR. Omeprazole overdose. Hum Exp Toxicol. 1993 Nov;12(6):541-2.

Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 2013 Nov;38(9):1129-37.

Belhocine K, Vavasseur F, Volteau C, Flet L, Touchefeu Y, Bruley des Varannes S. Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole. BMC Gastroenterol. 2014 Jul 15;14:128.

Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol. 2016 Sep;27(5):408-414.

Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003 Dec;98(12):2616-20.

Asatryan A. D., Komarova N. L. Evolution of genetic instability in heterogeneous tumors. Journal of Theoretical Biology. 2016;396:1–12. doi: 10.1016/j.jtbi.2015.11.028.

Burrell R. A., Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Molecular Oncology. 2014;8(6):1095–1111. doi: 10.1016/j.molonc.2014.06.005.

Ferguson L. R., Chen H., Collins A. R., et al. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Seminars in Cancer Biology. 2015;35:S5–S24. doi: 10.1016/j.semcancer.2015.03.005.

Kohler J. E., Blass A. L., Liu J., Tai K., Soybel D. I. Antioxidant pre-treatment prevents omeprazole-induced toxicity in an in vitro model of infectious gastritis. Free Radical Biology and Medicine. 2010;49(5):786–791. doi: 10.1016/j.freeradbiomed.2010.05.034.

Wadhwa R., Song S., Lee J. S., Yao Y., Wei Q., Ajani J. A. Gastric cancer—molecular and clinical dimensions. Nature Reviews Clinical Oncology. 2013;10(11):643–655. doi: 10.1038/nrclinonc.2013.170.

Downes N., Foster J. Regulatory forum opinion piece: carcinogen risk assessment: the move from screens to science. Toxicologic Pathology. 2015;43(8):1064–1073. doi: 10.1177/0192623315598578.

Neumann H. G. Risk assessment of chemical carcinogens and thresholds. Critical Reviews in Toxicology. 2009;39(6):449–461. doi: 10.1080/10408440902810329.

Brambilla G., Mattioli F., Martelli A. Genotoxic and carcinogenic effects of gastrointestinal drugs. Mutagenesis. 2010;25(4):315–326. doi: 10.1093/mutage/geq025.

Brambilla G., Mattioli F., Robbiano L., Martelli A. Genotoxicity and carcinogenicity testing of pharmaceuticals: correlations between induction of DNA lesions and carcinogenic activity. Mutation Research/Reviews in Mutation Research. 2010;705(1):20–39. doi: 10.1016/j.mrrev.2010.02.004.

Brambilla G., Mattioli F., Robbiano L., Martelli A. Update of carcinogenicity studies in animals and humans of 535 marketed pharmaceuticals. Mutation Research/Reviews in Mutation Research. 2012;750(1):1–51. doi: 10.1016/j.mrrev.2011.09.002.

Brambilla G., Mattioli F., Robbiano L., Martelli A. Studies on genotoxicity and carcinogenicity of antibacterial, antiviral, antimalarial and antifungal drugs. Mutagenesis. 2012;27(4):387–413. doi: 10.1093/mutage/ger094.

Jain K. S., Shah A. K., Bariwal J., et al. Recent advances in proton pump inhibitors and management of acid-peptic disorders. Bioorganic and Medicinal Chemistry. 2007;15(3):1181–1205. doi: 10.1016/j.bmc.2006.07.068.

Ferrua M. J., Singh R. P. Modeling the fluid dynamics in a human stomach to gain insight of food digestion. Journal of Food Science. 2010;75(7):R151–R162. doi: 10.1111/j.1750-3841.2010.01748.x.

Kenneth R., Mcquaid M. D. Fármacos usados no tratamento de doenças gastrintesti-nais. In: Katzung B. G., Masters S. B., Trevor A. J., editors. Farmacologia básica e clínica. 12. Porto Alegre: AMGH; 2014. pp. 1081–1092.

Wallace J. L., Sharkey K. A. Farmacoterapia da acidez gástrica, úlcera pépticas e doença do refluxo gastroesofágico. In: Brunton L. L., Chabner B. A., Knolmann B. C., editors. As bases farmacológicas da terapêutica de Goodman & Gil-man. 12. Porto Alegre: AMGH; 2012. pp. 1309–1321.

Schubert M. L. Gastric secretion. Current Opinion in Gastroenterology. 2014;30(6):578–582. doi: 10.1097/MOG.0000000000000125.

Yao X., Forte J. G. Cell biology of acid secretion by the parietal cell. Annual Review of Physiology. 2003;65(1):103–131. doi: 10.1146/annurev.physiol.65.072302.114200.

Hong C. Y., Lee S. Y., Ryu S. H., Lee S. S., Kim M. Whole-Genome De Novo Sequencing of the lignin-degrading wood rot Fungus Phanerochaete chrysosporium (ATCC 20696) Genome Announcements. 2017;5(32) doi: 10.1128/genomea.00731-17.

Dias N., Santos P., Pinto M., et al. Análise de prontuários de pacientes com gastrite em um hospital na região oeste ii do estado de Goiás. Revista Eletrônica Faculdade Montes Belos. 2015;8(1):1–9.

Bansal V. K., Goel R. K. Gastroprotective effect of Acacia nilotica young seedless pod extract: Role of polyphenolic constituents. Asian Pacific Journal of Tropical Medicine. 2012;5(7):523–528. doi: 10.1016/S1995-7645(12)60092-3.

Song K. H., Woo S. R., Chung J. Y., et al. REP1 inhibits FOXO3-mediated apoptosis to promote cancer cell survival. Cell Death & Disease. 2017;8(1, article e2536) doi: 10.1038/cddis.2016.462.

Brzozowski T., Ptak-Belowska A., Kwiecien S., et al. Novel concept in the mechanism of injury and protection of gastric mucosa: role of renin-angiotensin system and active metabolites of angiotensin. Current Medicinal Chemistry. 2012;19(1):55–62. doi: 10.2174/092986712803413953.

Ballweg R., Schozer F., Elliott K., et al. Multiscale positive feedbacks contribute to unidirectional gastric disease progression induced by Helicobacter pylori infection. BMC Systems Biology. 2017;11(1) doi: 10.1186/s12918-017-0497-y.

Willemijntje A. H., Pankaj J. P. Agents used for control of gastric acidity and treatment of peptic ulcers and gastroesophageal reflux disease. In: Joel G. H., Lee E. L., editors. The Pharmacological Basis of Therapeutics. Britain: McGraw-Hill Medical Publishing Division; 2001. pp. 1010–1011.

Malfertheiner P., Chan F. K. L., Mccoll K. E. L. Peptic ulcer disease. The Lancet. 2009;374(9699):1449–1461. doi: 10.1016/S0140-6736(09)60938-7.

Graham D. Y. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World Journal of Gastroenterology: WJG. 2014;20(18):5191–5204. doi: 10.3748/wjg.v20.i18.5191.

Cartágenes V. D.'. A., Martins L. C., Carneiro L. M., Barile K. A. d. S., Corvelo T. C. Helicobacter pylori em crianças e associação de cepas CagA na transmissão mãe-filho na Amazônia brasileira. Revista da Sociedade Brasileira de Medicina Tropical. 2009;42(3):298–302. doi: 10.1590/S0037-86822009000300011.

Machado K. C., Oliveira G. L. S., de Sousa É. B. V., et al. Spectroscopic studies on the in vitro antioxidant capacity of isopentyl ferulate. Chemico-Biological Interactions. 2015;225:47–53. doi: 10.1016/j.cbi.2014.11.008.

Konturek S. J., Konturek P. C., Brzozowski T., Konturek J. W., Pawlik W. W. From nerves and hormones to bacteria in the stomach; Nobel prize for achievements in gastrology during last century. Journal of Physiology and Pharmacology. 2005;56(4):507–530.

Fiocca R., Mastracci L., Attwood S. E., et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Alimentary Pharmacology & Therapeutics. 2012;36(10):959–971. doi: 10.1111/apt.12052.

Polanco Allué I. Microbiota y enfermedades gastrointestinales. Anales de Pediatría (English Edition) 2015;83(6):443.e1–443.e5. doi: 10.1016/j.anpede.2015.11.003.

Kalayci M., Kocdor M. A., Kuloglu T., et al. Comparison of the therapeutic effects of sildenafil citrate, heparin and neuropeptides in a rat model of acetic acid-induced gastric ulcer. Life Sciences. 2017;186:102–110. doi: 10.1016/j.lfs.2017.08.013.

Lanas A., Chan F. K. L. Peptic ulcer disease. The Lancet. 2017;390(10094):613–624. doi: 10.1016/S0140-6736(16)32404-7.

Mnich E., Kowalewicz-Kulbat M., Sicińska P., et al. Impact of Helicobacter pylori on the healing process of the gastric barrier. World Journal of Gastroenterology. 2016;22(33):7536–7558. doi: 10.3748/wjg.v22.i33.7536.

Pandya H. B., Agravat H. H., Patel J. S. Prevalence of specific Helicobacter Pylori CagA, vacA, iceA, ureC genotypes and its clinical relevance in the patients with acid-peptic diseases. Journal of Clinical and Diagnostic Research. 2017;11(8):23–26. doi: 10.7860/JCDR/2017/27812.10457.

Numico G., Fusco V., Franco P., Roila F. Proton pump inhibitors in cancer patients: how useful they are? A review of the most common indications for their use. Critical Reviews In Oncology/hematology. 2017;111:144–151. doi: 10.1016/j.critrevonc.2017.01.014.

Savarino V., Dulbecco P., de Bortoli N., Ottonello A., Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. European Journal Of Internal Medicine. 2017;37:19–24. doi: 10.1016/j.ejim.2016.10.007.

Minalyan A., Benhammou J. N., Artashesyan A., Lewis M. S., Pise-Gna J. R. Autoimmune atrophic gastritis: current perspectives. Clinical and Experimental Gastroenterology. 2017;10:19–27. doi: 10.2147/CEG.S109123.

Schubert M. L., Peura D. A. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–1860. doi: 10.1053/j.gastro.2008.05.021.

Novotna A., Srovnalova A., Svecarova M., Korhonova M., Bartonkova I., Dvorak Z. Differential effects of omeprazole and lansoprazole enantiomers on aryl hydrocarbon receptor in human hepatocytes and cell lines. PLoS One. 2014;9(6, article e98711) doi: 10.1371/journal.pone.0098711.

Park S., Hyun Y. J., Kim Y. R., et al. Effects of CYP2C19 genetic polymorphisms on PK/PD responses of omeprazole in Korean healthy volunteers. Journal of Korean Medical Science. 2017;32(5):729–736. doi: 10.3346/jkms.2017.32.5.729.

Hoogerwerf W. A., Pasricha P. J. Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. In: Goodman A. G., editor. The Pharmacological Basis of Therapeutics. 11. Mc Graw Hill; 2006. pp. 967–981.

Wang X., Li S. Protein mislocalization: mechanisms, functions and clinical applications in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2014;1846(1):13–25. doi: 10.1016/j.bbcan.2014.03.006.

Novotna A., Korhonova M., Bartonkova I., et al. Enantiospecific effects of ketoconazole on aryl hydrocarbon receptor. PLoS One. 2014;9(7, article e101832) doi: 10.1371/journal.pone.0101832.

Holguín H., Ceballos M., Amariles P. Clinical relevance of clopidogrel and omeprazole interaction: systematic review. Revista Colombiana de Cardiología. 2012;19(1):25–32. doi: 10.1016/S0120-5633(12)70100-6.

Lahner E., Galli G., Esposito G., Pilozzi E., Corleto V. D., Annibale B. Updated features associated with type 1 gastric carcinoids patients: a single-center study. Scandinavian Journal of Gastroenterology. 2014;49(12):1447–1455. doi: 10.3109/00365521.2014.968859.

Muthuraman A., Sood S. Antisecretory, antioxidative and antiapoptotic effects of montelukast on pyloric ligation and water immersion stress induced peptic ulcer in rat. Pros-taglandins, Leukotrienes and Essential Fatty Acids. 2010;83(1):55–60. doi: 10.1016/j.plefa.2010.01.003.

El-Ashmawy N. E., Khedr E. G., El-Bahrawy H. A., Selim H. M. Nebivolol prevents indomethacin-induced gastric ulcer in rats. Journal of Immunotoxicology. 2016;13(4):580–589. doi: 10.3109/1547691X.2016.1142488.

Almasaudi S. B., el-Shitany N. A., Abbas A. T., et al. Antioxidant, anti-inflammatory, and antiulcer potential of manuka honey against gastric ulcer in rats. Oxidative Medicine and Cellular Longevity. 2016;2016:10. doi: 10.1155/2016/3643824.3643824

Blandizzi C., Gherardi G., Marveggio C., Natale G., Carignani D., del Tacca M. Mechanisms of protection by omeprazole against experimental gastric mucosal damage in rats. Digestion. 1995;56(3):220–229. doi: 10.1159/000201247.

El-Naga R. N. Apocynin protects against ethanol-induced gastric ulcer in rats by attenuating the upregulation of NADPH oxidases 1 and 4. Chemico-Biological Interactions. 2015;242:317–326. doi: 10.1016/j.cbi.2015.10.018.

Al Batran R., Al-Bayaty F., Jamil Al-Obaidi M. M., et al. In vivo antioxidant and antiulcer activity of Parkia speciosa ethanolic leaf extract against ethanol-induced gastric ulcer in rats. PLoS One. 2013;8(5, article e64751) doi: 10.1371/journal.pone.0064751.

Albaayit S. F. A., Abba Y., Abdullah R., Abdullah N. Prophylactic effects of Clausena excavata Burum. f. leaf extract in ethanol-induced gastric ulcers. Drug Design, Development and Therapy. 2016;10:1973–1986. doi: 10.2147/DDDT.S103993.

Mahmoud-Awny M., Attia A. S., Abd-Ellah M. F., El-Abhar H. S. Mangiferin mitigates gastric ulcer in ischemia/reperfused rats: involvement of PPAR-γ, NF-κB and Nrf 2/HO-1 signaling pathways. PLoS One. 2015;10(7, article e0132497) doi: 10.1371/journal.pone.0132497.

Ahn J. S., Eom C. S., Jeon C. Y., Park S. M. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World Journal of Gastroenterology. 2013;19(16):2560–2568. doi: 10.3748/wjg.v19.i16.2560.

Asghar W., Pittman E., Jamali F. Comparative efficacy of esomeprazole and omeprazole: racemate to single enantiomer switch. DARU Journal of Pharmaceutical Sciences. 2015;23(1):p. 50. doi: 10.1186/s40199-015-0133-6.

Kajiura S., Hosokawa A., Ueda A., et al. Effective healing of endoscopic submucosal dissection-induced ulcers by a single week of proton pump inhibitor treatment: a retrospective study. BMC Research Notes. 2015;8(1):p. 150. doi: 10.1186/s13104-015-1111-2.

Blandizzi C., Natale G., Gherardi G., et al. Gastroprotective effects of pantoprazole against experimental mucosal damage. Fundamental & Clinical Pharmacology. 2000;14(2):89–99. doi: 10.1111/j.1472-8206.2000.tb00396.x.

Zhang F., Wang L., Wang J. J., Luo P. F., Wang X. T., Xia Z. F. The caspase-1 inhibitor AC-YVAD-CMK attenuates acute gastric injury in mice: involvement of silencing NLRP3 inflammasome activities. Scientific Reports. 2016;6(1, article 24166) doi: 10.1038/srep24166.

Kuramoto T., Umegaki E., Nouda S., et al. Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterology. 2013;13(1):p. 85. doi: 10.1186/1471-230X-13-85.

Bateman D. N., Colin-Jones D., Hartz S., et al. Mortality study of 18 000 patients treated with omeprazole. Gut. 2003;52(7):942–946. doi: 10.1136/gut.52.7.942.

Choi Y., Han H., Shin D., Lim K. S., Yu K. S. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. Drug Design, Development and Therapy. 2015;9:4127–4135. doi: 10.2147/DDDT.S86725.

Nagahara A., Suzuki T., Nagata N., et al. A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis. Journal of Gastroenterology. 2014;49(12):1536–1547. doi: 10.1007/s00535-013-0925-8.

Nishida T., Tsujii M., Tanimura H., et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. World Journal of Gastroenterology: WJG. 2014;20(15):4362–4369. doi: 10.3748/wjg.v20.i15.4362.

Birkmann K., Junge H. K., Maischberger E., Wehrli Eser M., Schwarzwald C. C. Efficacy of omeprazole powder paste or enteric-coated formulation in healing of gastric ulcers in horses. Journal of Veterinary Internal Medicine. 2014;28(3):925–933. doi: 10.1111/jvim.12341.

Ibrahim M. Y., Hashim N. M., Dhiyaaldeen S. M., et al. Acute toxicity and gastroprotection studies of a new Schiff base derived manganese (II) complex against HCl/ethanol-induced gastric ulcerations in rats. Scientific Reports. 2016;6(1, article 26819) doi: 10.1038/srep26819.

Gao W., Li H.-Y., Wang L.-X., et al. Protective effect of omeprazole on gastric mucosal of cirrhotic portal hypertension rats. Asian Pacific Journal of Tropical Medicine. 2014;7(5):402–406. doi: 10.1016/s1995-7645(14)60065-1.

Kim Y. J., Lee J. S., Hong K. S., Chung J. W., Kim J. H., Hahm K. B. Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression. Cancer Prevention Research. 2010;3(8):963–974. doi: 10.1158/1940-6207.CAPR-10-0033.

Puiac S., Sem X., Negrea A., Rhen M. Small-molecular virulence inhibitors show divergent and immunomodulatory effects in infection models of Salmonella enterica serovar Typhimurium. International Journal of Antimicrobial Agents. 2011;38(5):409–416. doi: 10.1016/j.ijantimicag.2011.06.009.

Chanchal S. K., Mahajan U. B., Siddharth S., et al. In vivo and in vitro protective effects of omeprazole against neuropathic pain. Scientific Reports. 2016;6(1):1–10. doi: 10.1038/srep30007.

Biswas K., Bandyopadhyay U., Chattopadhyay I., Varadaraj A., Ali E., Banerjee R. K. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. Journal of Biological Chemistry. 2003;278(13):10993–11001. doi: 10.1074/jbc.M210328200.

Patel A., Zhang S., Shrestha A. K., Maturu P., Moorthy B., Shivanna B. Omeprazole induces heme oxygenase-1 in fetal human pulmonary microvascular endothelial cells via hydrogen peroxide-independent Nrf2 signaling pathway. Toxicology and Applied Pharmacology. 2016;311:26–33. doi: 10.1016/j.taap.2016.10.002.

Balza E., Piccioli P., Carta S., et al. Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance. Cell Death & Disease. 2016;7(7, article e2304) doi: 10.1038/cddis.2016.218.

Hashioka S., Klegeris A., Mcgeer P. L. Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity. Experimental Neurology. 2009;217(1):177–183. doi: 10.1016/j.expneurol.2009.02.002.

Song J.-W., Seo C.-S., Kim T.-I., et al. Protective effects of manassantin A against ethanol-induced gastric injury in rats. Biological and Pharmaceutical Bulletin. 2016;39(2):221–229. doi: 10.1248/bpb.b15-00642.

Zheng H., Chen Y., Zhang J., et al. Evaluation of protective effects of costunolide and dehydrocostuslactone on ethanol-induced gastric ulcer in mice based on multi-pathway regulation. Chemico-Biological Interactions. 2016;250:68–77. doi: 10.1016/j.cbi.2016.03.003.

Shimoyama A. T., Santin J. R., Machado I. D., et al. Antiulcerogenic activity of chlorogenic acid in different models of gastric ulcer. Naunyn-Schmiedeberg's Archives of Pharmacology. 2013;386(1):5–14. doi: 10.1007/s00210-012-0807-2.

Kengkoom K., Tirawanchai N., Angkhasirisap W., Ampawong S. Omeprazole preserves the RER in chief cells and enhances re epithelialization of parietal cells with SOD and AQP 4 up regulation in ethanol induced gastritis rats. Experimental and Therapeutic Medicine. 2017;14(6):5871–5880. doi: 10.3892/etm.2017.5270.

Fang Z., Tang J., Bai Y., et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. Journal of Experimental & Clinical Cancer Research. 2015;34(1):p. 86. doi: 10.1186/s13046-015-0198-6.

Hamdan D. I., Mahmoud M. F., Wink M., El-Shazly A. M. Effect of hesperidin and neohesperidin from bittersweet orange (Citrus aurantium var. bigaradia) peel on indomethacin-induced peptic ulcers in rats. Environmental Toxicology and Pharmacology. 2014;37(3):907–915. doi: 10.1016/j.etap.2014.03.006.

Nassenstein C., Kerzel S., Braun A. Neurotrophins and neurotrophin receptors in allergic asthma. Progress in Brain Research. 2004;146:347–367. doi: 10.1016/S0079-6123(03)46022-6.

Mao S., Yang G., Li W., et al. Gastroprotective effects of astragaloside IV against acute gastric lesion in rats. PLoS One. 2016;11(2):p. e0148146. doi: 10.1371/journal.pone.0148146.

Sabat R., Grütz G., Warszawska K., et al. Biology of interleukin-10. Cytokine & Growth Factor Reviews. 2010;21(5):331–344. doi: 10.1016/j.cytogfr.2010.09.002.

Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harbor perspectives in biology. 2009;1(6) doi: 10.1101/cshperspect.a001651.

Wang J., Zhang T., Zhu L., Ma C., Wang S. Anti-ulcerogenic effect of Zuojin Pill against ethanol-induced acute gastric lesion in animal models. Journal of Ethnopharmacology. 2015;173:459–467. doi: 10.1016/j.jep.2015.04.017.

Choo B. K., Roh S. S. Berberine protects against esophageal mucosal damage in reflux esophagitis by suppressing proinflammatory cytokines. Experimental and Therapeutic Medicine. 2013;6(3):663–670. doi: 10.3892/etm.2013.1202.

Ghebremariam Y. T., Cooke J. P., Gerhart W., et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. Journal of Translational Medicine. 2015;13(1):1–20. doi: 10.1186/s12967-015-0614-x.

Liu Z., Luo Y., Cheng Y., et al. Gastrin attenuates ischemia-reperfusion-induced intestinal injury in rats. Experimental Biology and Medicine. 2016;241(8):873–881. doi: 10.1177/1535370216630179.

Laura R. P., Dong D., Reynolds W. F., Maki R. A. T47D cells expressing myeloperoxidase are able to process, traffic and store the mature protein in lysosomes: studies in T47D cells reveal a role for Cys319 in MPO biosynthesis that precedes its known role in intermolecular disulfide bond formation. PLoS One. 2016;11(2, article e0149391) doi: 10.1371/journal.pone.0149391.

Richter J., Jimenez J., Nagatomo T., et al. Proton-pump inhibitor omeprazole attenuates hyperoxia induced lung injury. Journal of Translational Medicine. 2016;14(1):p. 247. doi: 10.1186/s12967-016-1009-3.

Niece K. L., Boyd N. K., Akers K. S. In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrobial Agents and Chemotherapy. 2015;59(9):5548–5554. doi: 10.1128/AAC.00884-15.

Kumar, R., Saha, P., Kumar, Y., Sahana, S., Dubey, A., & Prakash, O. (2020). A review on diabetes mellitus: type1 & Type2. World Journal of Pharmacy and Pharmaceutical Sciences, 9(10), 838-850.

Kumar, R., Saha, P., Lokare, P., Datta, K., Selvakumar, P., & Chourasia, A. (2022). A systemic review of Ocimum sanctum (Tulsi): Morphological characteristics, phytoconstituents and therapeutic applications. International Journal for Research in Applied Sciences and Biotechnology, 9(2), 221-226.

Kumar, R., & Saha, P. (2022). A review on artificial intelligence and machine learning to improve cancer management and drug discovery. International Journal for Research in Applied Sciences and Biotechnology, 9(3), 149-156.

Bind, A., Das, S., Singh, V. D., Kumar, R., Chourasia, A., & Saha, P. (2020). Natural bioactives for the potential management of gastric ulceration. Turkish Journal of Physiotherapy and Rehabilitation, 32(3), 221-226.

Nyarko, R. O., Awuchi, C. G., Kumar, R., Boateng, E., Kahwa, I., Boateng, P. O., ... & Saha, P. (2022). Effect of Calotropis Procera Extract on Appetitte, Body Weight & Lipid Profile in Cafeteria Diet Induced Obesity in Experimental Animal. Journal for Research in Applied Sciences and Biotechnology, 1(3), 107-113

Botelho-Nevers E., Singh S., Chiche L., Raoult D. Effect of omeprazole on vacuole size in Coxiella burnetii -infected cells. Journal of Infection. 2013;66(3):288–289. doi: 10.1016/j.jinf.2012.10.006.

Lou D. I., Hussmann J. A., Mcbee R. M., et al. High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proceedings of the National Academy of Sciences of the United States of the America. 2013;110(49):19872–19877. doi: 10.1073/pnas.1319590110.